Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/189165
Title: | Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management |
Author: | Bellmunt, Joaquim Valderrama, Begoña P. Puente, Javier Grande, Enrique Bolós, M. Victoria Lainez, Nuria Vázquez, Sergio Maroto, Pablo Climent, Miguel Ángel García del Muro Solans, Xavier Arranz, José Ángel Durán, Ignacio |
Keywords: | Càncer de bufeta Bladder cancer |
Issue Date: | 1-Jun-2022 |
Publisher: | Elsevier BV |
Abstract: | Management of first-line advanced urothelial carcinoma (UC) has consisted during the past three decades in the administration of platinum-based chemotherapy followed by observation. Despite moderate to high response rates to first-line treatment, most patients will relapse shortly after and the outcomes with subsequent therapies are poor with 5-year overall survival rates of 5% in the pre-immunotherapy era. Nonetheless, recent therapeutic developments including the paradigm shift of first-line maintenance therapy with avelumab after response or stabilization on platinum-based chemotherapy, along with the incorporation of new drug classes in further lines of treatment such as antibody drug-conjugates and fibroblast growth factor receptor inhibitors have reshaped the field leading to better outcomes in this patient population. This article reviews the current state of the art with an overview on UC management, recent advances, and the upcoming strategies currently in development in advanced UC with an insight into the biology of this disease. |
Note: | Reproducció del document publicat a: https://doi.org/10.1016/j.critrevonc.2022.103683 |
It is part of: | Critical Reviews in Oncology/Hematology, 2022, vol. 174, p. 103683 |
URI: | http://hdl.handle.net/2445/189165 |
Related resource: | https://doi.org/10.1016/j.critrevonc.2022.103683 |
ISSN: | 1879-0461 |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1-s2.0-S104084282200107X-main.pdf | 2.12 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License